Business Context and Reporting Period
The source text identifies the registrant as Gemphire Therapeutics Inc., not Metavia Inc. This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2018, filed November 8, 2018. Gemphire is a clinical-stage biopharmaceutical company developing gemcabene for dyslipidemia and NAFLD/NASH. It has no approved products and has generated no revenue.
Financial Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expense | $2.4 million | $7.0 million |
| Research and development expense | $3.5 million | $12.5 million |
| Total operating expenses | $5.9 million | $19.5 million |
| Net loss | $6.1 million | $20.0 million |
| Basic and diluted loss per share | $0.43 loss | $1.46 loss |
| Net cash used in operating activities | $17.8 million |
Cash and cash equivalents were $23.8 million at September 30, 2018, compared with $18.5 million at December 31, 2017. Total assets were $24.9 million and stockholders’ equity was $10.9 million. The accumulated deficit was $80.5 million.
Term-loan liabilities totaled $10.1 million, consisting of $3.7 million current and $6.4 million long term. The loan carries a floating interest rate based on prime and matures February 1, 2021. The company reported no investing cash flows and $23.1 million of net financing cash inflows, primarily from its February 2018 equity offering. Cash increased by $5.3 million during the nine-month period.
Material Changes Versus the Prior Comparable Period
- Third-quarter net loss declined to $6.1 million from $8.7 million; nine-month net loss declined to $20.0 million from $26.7 million.
- Third-quarter operating expenses decreased $2.6 million, primarily because research and development expense declined $2.9 million as clinical activity decreased.
- Nine-month research and development expense decreased $5.1 million, while general and administrative expense decreased $1.9 million, largely reflecting lower separation-related costs than in 2017.
- Interest expense increased to $0.2 million for the quarter and $0.5 million for the nine months, compared with $0.1 million for each prior comparable period, due primarily to the term loan.
- The company issued 3,592,858 common shares in its February 2018 follow-on offering and received approximately $23.1 million in net proceeds. Shares outstanding increased to 14,265,411 from 10,633,042 at year-end 2017.
- In September 2018, the company approved a workforce reduction affecting five employees, approximately 33% of its workforce, to reduce costs and conserve cash.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expects cash and cash equivalents to fund operations for at least the next 12 months from the filing date, but states that additional capital will be required to continue development and operations.
- The company expects continued operating losses and does not expect revenue unless gemcabene obtains regulatory approval and is commercialized. Additional financing may be obtained through equity, debt, collaborations, strategic alliances, or licensing arrangements, with potential dilution or restrictive terms.
- The FDA did not lift the partial clinical hold on gemcabene studies longer than six months and requested additional preclinical studies. The company expected to submit the additional data in the second quarter of 2019. An End-of-Phase 2 meeting was delayed until the hold is lifted.
- The pediatric NAFLD trial was halted early after the first three patients showed efficacy endpoints that were not improving or, in multiple cases, worsened. The FPL/NASH trial continued, with top-line data expected in the second quarter of 2019.
- The company did not expect to satisfy the conditions required to draw the remaining $5.0 million loan tranche by November 30, 2018.
- Because a required preclinical event had not occurred by November 1, 2018, the company began making monthly principal and interest payments on the term loan rather than continuing interest-only payments.
- The loan agreement may require restricted cash equal to 100% of amounts owed or full repayment if the preclinical event does not occur by September 30, 2019 or unrestricted cash falls below $18 million before that event. The agreement also includes customary default provisions, covenants, a 10% final payment fee, and potential success and prepayment fees.
- The September workforce reduction generated approximately $1.3 million of third-quarter expense, comprising $0.6 million in general and administrative expense and $0.7 million in research and development expense. Total estimated severance-related charges were approximately $1.6 million, including cash and non-cash components.
- The amended Pfizer license includes potential milestone payments of up to $37 million and tiered royalties on future sales. No milestone or royalty payments had been triggered as of September 30, 2018.
- Management stated that disclosure controls and procedures were effective as of September 30, 2018 and that there were no material changes in internal control over financial reporting during the quarter.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for Gemphire Therapeutics Inc., while the request metadata names Metavia Inc.
- Verify cash runway assumptions against the company’s ongoing operating cash burn, mandatory term-loan amortization, and inability to access the additional $5.0 million tranche.
- Review the FDA partial clinical hold, requested preclinical studies, and timing and outcome of any subsequent FDA submissions.
- Assess the pediatric NAFLD trial halt and the status and results of the FPL/NASH trial.
- Reconcile the workforce-reduction charges, executive departures, accelerated option vesting, and potential operational impact.
- Review the term-loan covenants, restricted-cash or repayment triggers, final payment fee, and other contingent fees.
- Consider dilution from future financing needs, outstanding options for 2.8 million shares, and warrants for approximately 1.0 million shares.
- Review the Pfizer license’s development obligations, termination provisions, milestone payments, and royalty terms.